News Press Releases

NeuroMetrix to Present at the Digital Medicine Showcase 2017: At the Intersection of Technology and Medicine

NURO | January 6, 2017

NeuroMetrix to Present at the Digital Medicine Showcase 2017: At the Intersection of Technology and Medicine

NeuroMetrix, Inc. (NASDAQ:NURO, NUROW) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Digital Medicine Showcase 2017 at the Parc 55 San Francisco in San Francisco, CA. The Digital Medicine Showcase brings together innovative companies showcasing clinically impactful digital health technologies, venture capital and private equity investors, pharma executives and professional advisors. Dr. Gozani will present the Company's Quell^® Wearable Pain Relief Technology^™ on Wednesday, January 11, 2017, at 10:45 a.m. Pacific Time.

About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck^®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.